Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
RegulatoryapprovedGuardant360® CDxVEPPANUPositive
AI Analysis
Summary
Guardant Health received FDA approval for Guardant360® CDx as a companion diagnostic for Arvinas and Pfizer's vepdegestrant (VEPPANU) in patients with ER+/HER2- advanced breast cancer with ESR1 mutations. This approval enables the use of the diagnostic test to identify patients eligible for the breast cancer treatment.
Outcome Details
FDA Approval for Guardant360® CDx as a Companion Diagnostic for vepdegestrant
Importance:8/10
Sentiment:
0.85
FDA ApprovalCompanion DiagnosticBreast CancerESR1 MutationsRegulatory Approval
Related Companies
Read the original article
Published by yahoo_finance on May 4, 2026 12:05 PM